Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Fulcrum Therapeutics, Inc. (FULC) is a Biotechnology company based in US with a market capitalization of $199.1M. Free cash flow was negative at -$60.4M. This page tracks FULC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 45 employees · IPO Jul 18, 2019
Valuation
Valuation & price
$6.69as of May 17, 2026· -54.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.57
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$199.1M
Market cap
—
Revenue growth (YoY)
20.8%
Gross margin
-$60.4M
Free cash flow (USD)
-$345.9M
Net debt
Net cash position
2.2%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2017 → 2025
Free cash flow by year
2017 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
2
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed Apr 27, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJul 20, 2026Filing
Insider Buy $595KTANG KEVIN · 10% Owner · $594.7K
- Insider buyJul 15, 2026Filing
Insider Buy $891KTANG KEVIN · 10% Owner · $891.1K
- Insider sellJun 30, 2026Filing
Insider Sell $66K · 10b5-1 PlanEzekowitz Alan · Director · $65.6K
- 8-K eventJun 25, 2026Filing
Annual Meeting Results
- 8-K eventJun 11, 2026Filing
Restructuring Plan Approved
- 8-K eventJun 4, 2026Filing
Restructuring Plan Approved
- 8-K eventJun 1, 2026Filing
Program Discontinuation
- 8-K eventApr 27, 2026Filing
Business Update and Financial Results
- Quarterly reportApr 27, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Fulcrum Therapeutics, Inc.'s market cap?
Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of $199.1M.
What is FULC's P/E ratio?
A meaningful P/E ratio is not available for FULC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is FULC's price-to-book (P/B) ratio?
FULC trades at 0.57 times book value per share.
Are insiders buying FULC stock?
Yes — SEC Form 4 filings show 2 open-market insider buys and 1 sell at Fulcrum Therapeutics, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.